Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Inventory (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Inventory for 16 consecutive years, with $18.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Inventory fell 21.09% to $18.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $18.8 million, a 21.09% decrease, with the full-year FY2025 number at $18.8 million, down 21.09% from a year prior.
  • Inventory was $18.8 million for Q4 2025 at Anika Therapeutics, up from $16.3 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $51.5 million in Q2 2024 to a low of $16.3 million in Q3 2025.
  • A 5-year average of $34.7 million and a median of $36.6 million in 2021 define the central range for Inventory.
  • Peak YoY movement for Inventory: rose 20.8% in 2024, then plummeted 67.12% in 2025.
  • Anika Therapeutics' Inventory stood at $36.0 million in 2021, then increased by 10.43% to $39.8 million in 2022, then plummeted by 38.57% to $24.4 million in 2023, then decreased by 2.53% to $23.8 million in 2024, then decreased by 21.09% to $18.8 million in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Inventory are $18.8 million (Q4 2025), $16.3 million (Q3 2025), and $16.9 million (Q2 2025).